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Summary Systemic toxicity is usually the dose-limiting factor in cancer chemotherapy. Regional
chemotherapy is therefore an attractive strategy in the treatment of liver metastasis. Two ways of regional
chemotherapy, hepatic artery infusion (HAI) and isolated liver perfusion (ILP), were compared investigating
the difference in toxicity with tissue and biofluid concentrations of mitomycin C (MMC). In wistar derived
WAG rats the maximally tolerated dose ofmitomycin C via HAI was 1.2 mg kg-'. Body weight measurements
after HAI with doses higher than 1.2 mg kg- ' suggest both an acute and delayed toxic effect of mitomycin C
since the time weight curves were triphasic: a rapid weight loss, a steady state and a second fall in weight
phase. These rats died due to systemic toxicity. ILP with 4.8 mg kg-' was associated with no signs of systemic
toxicity and only transient mild hepatotoxicity. ILP with 6.0 mg kg-' was fatal mainly due to hepatic toxicity.
The four times higher maximally tolerated dose in ILP resulted in a 4-5 times higher peak concentration of
mitomycin C in liver tissue, while the plasma concentration remained significantly lower than in the HAI
treated rats. In the tumour tissue a 500% higher concentration of mitomycin C was measured in the ILP with
4.8 mg kg-' than in HAI with 1.2 mg kg-' treated rats. We demonstrated that when mitomycin C was
administered by ILP a 400% higher dose could be safely administered and resulted in a five times higher
tumour tissue concentration. In view of the steep dose-response curve of this alkylating agent this opens new
perspectives for the treatment of liver metastasis.
The liver is a major site of metastatic spread of primary
colorectal cancer; in as many as 30% of the patients it is also
the sole site of initial tumour recurrence (Sugarbaker et al.,
1985). At the time of operation for the primary tumour
approximately 5% of patients with colorectal cancer have
resectable liver metastases (Foster & Lundy, 1981). Another
5% will develop resectable metastases confined to the liver
after resection of the primary tumour (Foster & Berman,
1977; Adson, 1983). These patients can be cured by surgery
and a 5-year survival rate of about 35% can be achieved
(Foster & Lundy, 1981; Adson et al., 1984; August et al.,
1985; Iwatsuki et al., 1986).
Unfortunately, in the majority (75%) of the patients with
colorectal cancer metastases confined to the liver, the tumour
is not resectable. These patients are eligible for locoregional
therapies. The rationale of regional administration of chemo-
therapy is based on the concept of achieving a high local
concentration, while minimising systemic drug levels and,
accordingly, reducing dose limiting systemic side-effects
(Collins, 1984). For most chemotherapeutic agents steep
dose-response curves can be demonstrated. Therefore, high
drug concentrations are important for both sensitive and
resistant tumour cells. For resistant cells extremely high
exposure is required for adequate cell kill (Slee et al., 1987;
Kuppen et al., 1988).
Exploiting high extraction ratios of the fluoropyrimidines
(Chen & Gross, 1980), currently the most effective drugs in
colorectal cancer treatment (Moertel, 1978), hepatic artery
infusion has initially met with some success (Balch et al.,
1983), albeit with considerable dose limiting morbidity (Velde
et al., 1987). In order to obtain cures, isolated liver perfusion
(ILP) has been developed in dogs and pigs as a treatment
modality that maximises drug concentration in the target
organ and at the same time shields the organism from
systemic toxicity (Aigner et al., 1982; Skibba et al., 1983;
Velde et al., 1986). Since no tumour models are available in
large animals the relationship between maximally tolerated
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dose and effectiveness of ILP in the treatment of hepatic
metastases could not be investigated. Therefore our group
developed an in vivo method of ILP in a rat colorectal cancer
hepatic metastasis model (Brauw et al., 1988). In the present
study mitomycin C was chosen as the chemotherapeutic drug
since the cytotoxic action of mitomycin C is dose related
(Bruijn et al., 1988; Wallner & Li, 1987), the cytotoxic action
of mitomycin C is non-cell-cycle-phase specific (Iyer &
Szybalski, 1964), and mitomycin C has been reported to be a
promising drug against colorectal cancer (Crooke & Bradner,
1976; Doll et al., 1985). Furthermore, the liver is the major
organ in the elimination of mitomycin C (Kerpel-Fronius et
al., 1988).
In our rat model we compared the toxicity pattern, the
maximally tolerated dose and the liver, tumour and plasma
concentrations of mitomycin C in experimental isolated liver
perfusion and in hepatic artery infusion, which is a clinically
extensively applied technique.
Aigner et al. (1988) and Schwemmle et al. (1987) have
already treated patients successfully with isolated liver per-
fusion despite having not yet treated with maximally
tolerated doses. In our surgical department a clinical dose
optimisation study with mitomycin C in isolated liver per-
fusion is ongoing.
Materials and methods
Rats
Wistar derived, inbred male WAG/Ola rats (Harlan/CPB,
Zeist, The Netherlands) were used. The weight of the rats
was 320-400g in the toxicity study and 300-350g in the
tissue and plasma concentration measurement study. They
were fed laboratory chow and water ad libitum.
Surgicalprocedures
All operative procedures were carried out under clean but
not sterile conditions, using a microscope (Applied Fiber-
optics, Southbridge, MA, USA) at 20 times magnification.
Anaesthesia was induced and maintained using ether.
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Isolated liverperfusion (Brauw et al., 1988)
Briefly, a midline abdominal incision was performed. Two
inflow limbs of the isolated circuit were established by insert-
ing one polyethylene (PE-10: o.d. 0.61 mm) cannula into the
pyloric branch of the portal vein with its tip in the portal
lumen and the other into the gastroduodenal branch of the
common hepatic artery with its tip in the hepatic artery (this
one did not exist in the technique described by de Brauw).
The outflow limb was a Quick-Cath (Travenol B.V., Utrecht,
The Netherlands) cannula (o.d. 2.1 mm) inserted in the caval
vein via a venotomy just above the right renal vein. The
distal part of the caval vein was clamped above the right
renal vein. Isolation of the liver was completed by clamping
the aorta above the coeliac axis, the suprahepatic caval vein
and the common hepatic artery plus portal vein. To prevent
ischaemic damage the intestines were exteriorised and packed
in ice. The perfusion circuit consisted of a low flow roller
pump (Watson Marlow, de Jong B.V., Rotterdam, The
Netherlands), an infusion pump (perfusor, B Braun Mel-
sungen, FR Germany), a collection reservoir/oxygenator with
pH-electrode (by Bakkenes, University of Leiden, The
Netherlands) and a heat-exchanger (warm water bath 42°C).
The recirculating system was primed with 30 ml Haemaccel
(Hoechst, Amsterdam, The Netherlands) with heparin (50 U)
and bicarbonate to adjust pH to 7.3. The flow rate into the
portal vein was 20 ml min' and 4.5 ml min-' into the
hepatic artery. The hepatic venous outflow was collected by
the intracaval cannula and was returned to the oxygenator by
gravity feed. Final Hb content of the perfusate was
0.6 mmol 1'. The perfusate was gassed during perfusion with
a mixture of 02/C02 (95%:5%) at a flow rate of 50 ml min-'
resulting in 99% oxygen saturation. The temperature of the
perfusate was measured just before entry into the portal vein
and regulated at 38°C.
In vivo perfusion was carried out for 25 min. At the end of
the ILP procedure a washout was performed with 8 ml
(4 x intravascular volume of the rat liver) of 0.9% NaCl of
38°C, which was perfused through the liver using the pyloric
vein cannula only.
Total operation time is 2.0-2.5 h.
Hepatic artery infusion
Hepatic artery infusion (HAI) was performed via the cannu-
lated gastroduodenal branch of the common hepatic artery
with the tip of the cannula in the hepatic artery. During the
5 min infusion the common hepatic artery was clamped to
prevent retrograde flow into the coeliac axis and the aorta.
Total operation time is 20-30 min.
Tumour modelfor the pharmacokinetic study
CC531 is a weakly immunogenic carcinoma of the colon,
syngeneic for WAG rats. The tumour is a dimethylhydrazine-
induced adenocarcinoma (Marquet et al., 1984). From this
WAG rat tumour a cell line was established. The cells were
cultured in RPMI 1640, supplemented with 10% heat-
inactivated fetal bovine serum (Gibco, Paisley, UK), 2 mM
glutamine, 50jig ml-' steptomycin and 50 U ml-' penicillin.
For tumour induction rats were inoculated with cells from
the CC531 cell line in passage 106. The rats underwent
laparotomy and 5 x 105 cells in 0.05 ml of normal saline were
subcapsularly injected into the right and left main lobes and
into the right accessory lobe of the liver. Ten days after
inoculation the cross-sectional area of the tumours was
37± 13mm2.
Cytostatic agent
Mitomycin C (Lic. Kyowa Hakko Kogyo Co. Ltd, Tokyo,
Japan) was dissolved in sterile 0.9% NaCl immediately
before administration, in a maximum concentration of
0.5 mgml-, to avoid crystallisation of mitomycin C.
Toxicity parameters
As parameters for systemic toxicity survival, weight, white
blood cell (WBC) count, and serum levels of sodium, potas-
sium, urea and creatinine were chosen. Serum levels of
bilirubin, serum glutamic-oxaloacetic transaminase (SGOT)
and serum glutamic-pyruvic transaminase (SGPT) were
determined to evaluate liver toxicity. Weight was determined
twice a week on days 3 and 7 after treatment. White blood
cell count was determined on days 3 and 7 of the first week
after treatment and then every 7 days.
SGOT, SGPT, bilirubin, sodium, potassium, urea and
creatinine were determined once a week on an automated
analysis apparatus: sodium, potassium, urea and creatinine
concentrations were determined on a Dimension (DuPont,
Wilmington, DE, USA) and bilirubin, SGOT, SGPT on a
RA 1000 (Technicon, Tarrytown, NY, USA). For the
analysis 1 ml was collected by a retro-orbital puncture.
Normal value range
Fifty blood samples were collected from healthy non-tumour
bearing control rats during this toxicity study to compute on
the basis of a normal distribution the 5% and 95% limits of
the normal value range of serum sodium, potassium,
creatinine, urea, bilirubin, SGOT and SGPT.
Sample pretreatment andhigh performance liquid
chromatography (HPLC) analysis
To terminate metabolism of mitomycin C the liver and
tumour tissue biopsies were immediately homogenised in
acetonitrile (Chemicals Limited, Walkerburn, UK; HPLC
grade). The samples were then snap frozen in liquid nitrogen
and stored at - 30°C. Before HPLC analysis the samples
were thawed and centrifuged at 6,000 r.p.m. Some 500-
1,000ptl of the supernatant was dried in a vacuum centrifuge
and dissolved in 5001il of the mobile phase (0.5 M phosphate
buffer pH 7.0 and acetonitrile (85%:15%). One hundred tll
of this solution was injected into the HPLC system (Tjaden
et al., 1987). Blood was centrifuged for 15 min at 2,000 r.p.m.
and plasma was stored at - 30°C. Before analysis, the
plasma was thawed and centrifuged at 6,000 r.p.m. The
supernatant was diluted with water and 100lil was injected
into the HPLC system (Tjaden et al., 1987).
Toxicity study
First the maximally tolerated dose for HAI was determined
by assigning non-tumour-bearing rats to six groups: (1) sham
HAI (n = 4); (2) to (5) 1.2 (n = 4), 1.5 (n = 6), 2.4 (n = 4),
3.6 (n = 4) and 4.8 (n = 4) mg MMC kg-' total body weight,
respectively. Subsequently non-tumour-bearing rats were
assigned to five groups for the ILP toxicity study: (1) sham
ILP (n
= 2); (2) to (5) 1 (n
= 2), 3 (n
= 4), 4 (n
= 6), and 5
(n = 4) times the maximally tolerated dose (1.2 mg kg-') for
HAI, respectively.
Tissue andplasma concentration study
Tumour-bearing rats were randomly assigned to three treat-
ment groups: (1) 1.2 mgkg-' (n = 5) via bolus HAI; (2)
1.2 mgkg-' (n = 6) and (3) 4.8 mgkg-' (n = 6) as a bolus in
the ILP circuit. During 25 min (perfusion (20 min) plus
washout (5 min) time) liver and tumour tissue biopsies were
taken. A liver biopsy was taken and a whole tumour was
excised at 5, 15 and 20 min after administration of
mitomycin C. From ILP as well as HAI treated rats a plasma
sample was collected at t = 25 min since at this time point
the plasma concentration is maximal in ILP treated rats (de
Brauw et al., 1988). All samples were prepared for HPLC
analysis.
To be able to calculate the tissue and plasma concentra-
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during the study, samples for calibration lines were prepared
identically and simultaneously: known concentrations of
mitomycin C were added to liver, tumour and plasma derived
from non-treated rats and immediately after the addition of
mitomycin C the samples were prepared for HPLC analysis.
Statistics
Data were computerised for statistical analysis. Initially
multivariate analysis of variance with repeated measurements
was used to compare weight and tissue concentration changes
across time versus the different treatment groups. Because of
significant interaction across these factors and thus complex
interpretation and description of the results, one-way analysis
of variance at each time point is used in the present presenta-
tion to compare the means of these factors in the different
groups. If significant differences were detected, a multiple
range test, according to Scheffe, was performed. P <0.05
was considered significant. To study the effect of the treat-
ment on white blood cell count within each group, a paired t
test was used for each group to compare the white blood cell
count at each time point with the starting value. For this
procedure P <0.01 was considered significant. Comparisons
between the plasma concentrations were carried out using
analysis of variance.
Results
Time-weight change curves
Hepatic artery infusion The average changes in weight after
mitomycin C treatment via HAI are illustrated in Figure la.
Control HAI with saline 0.9% had no effect on body weight.
Bolus HAI of 1.2 mg kg' resulted in a weight dip (mean
value 42 g) between days 8 and 12 and at about day 28 the
rats had regained their starting weight. None of the
1.2 mgkg-' treated rats died. When intermediate doses (1.5
and 2.4mgkg-') were administered the time-weight change
curves were characterised by a triphasic pattern: a rapid
weight loss, a steady state and a second fall in weight phase
(Figure la). Comparing the 1.5 and 2.4 mg kg-' treated
groups, the weight loss during the first phase was about 25 g
less in the 1.5 mg kg-' group (57 versus 83 g) and the steady
state phase was about 8 days longer (18 versus 10 days); it
resulted in significantly (P <0.05) less weight loss from day
17 until death in the 1.5 mg kg-' treated group than in the
2.4 mgkg' treated group. In the 3.6 mg kg-' treated group
one rat showed the triphasic pattern but the other three died
10-14 days after treatment after continuous rapid weight
loss. Administration of 4.8 mg mitomycin C kg- by HAI
was lethal to all rats within 5 days. These rats were losing
1Og body weight per day.
Isolated liver perfusion In contrast to the HAI groups, all
rats treated by ILP survived a mitomycin C dose of
4.8 mgkg' (4 x maximally tolerated dose for HAI). These
rats treated with high dose mitomycin C showed a dip in
their weight between days 9 and 12 (mean values: 58 g after
3.6mgkg-'; 67 after 4.8 mgkg-'). In contrast to the weight
loss in HAI treated rats, not all of the weight loss in ILP
treated rats was due to mitomycin C toxicity since a sham
ILP caused a mean weight loss of 27 g. Results are illustrated
in Figure lb.
Systemic andhepatic toxicity after HAI or ILP
Systemic toxicity During the follow-up, white blood cell
count was determined twice in the first week and then once a
week together with the electrolytic status (sodium, potassium,
urea and creatinine levels in serum).
Three days after administration of mitomycin C by HAI
all rats had a significantly decreased white blood cell count
(P <0.01) (Figure 2a). At day 7 the white blood cell count
regained normal values. In contrast in all ILP treated rats
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Figure 2 Average WBC count (x 1O' I )after administration of
bolus MMC a, by hepatic artery infusion: + 0 (n = 4), * 1.2
(n =4), 0 1.5 (n = 6), x 2.4 (n = 4) and O 3.6 (n =4) mg
MMC kg-' or b, in isolated liver perfusion: * 1.2 (n = 2), O 3.6
(n 4), A 4.8 (n 6) mg MMC kg-'.
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Figure 3 Average serum level of urea determined once a week
until death or to a maximum of 8 weeks in rats treated with
bolus MMC: 0 15 (n 6) or x 2.4 (n =4) mgkg- ' via the
hepatic artery, or with A 4.8 (n = 6) mg kg-'in isolated liver
perfusion setting. The horizontal lines are the 5% and 95% limits
of the normal value range. s.d. (vertical bars) is only indicated if
at least one rat had a urea level higher than the 95% limit.
Tissue andplasma concentration measurements
The toxicity study showed that the maximally tolerated doses
of mitomycin C in ILP and via HAI were 4.8 mg kg-' and
1.2 mg kg' respectively. The concentration of mitomycin C
in plasma was significantly lower in both ILP groups
(1.2hmgkg-' group, 22ngtml'; 4.8 mgkg-' group, 212ng
ml-') than in the HAi group (1.2 mg kg-' group, 539 ng
ml-'). The liver tissue concentrations of mitomycin C were
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Figure 4 Average serum level of bilirubin determined once a
week until death or to a maximum of 8 weeks following MMC
treatment in the isolated liver perfusion setting: * 1.2 (n = 2),
0 3.6 (n = 4) and A 4.8 (n = 6) mg MMC kg-', or via bolus
hepatic artery infusion: 0 1.5 (n = 6) mg MMCkg-'. The hori-
zontal lines are the 5% and 95% limits of the normal value
range. s.d. (vertical bars) is only indicated if at least one rat had a
bilirubin level higher than the 95% limit. The kinetics of hepatic
dysfunction seemed similar for serum glutamic-oxaloacetic trans-
aminase and serum glutamic-pyruvic transaminase.
of the same level in the two 1.2 mg kg-' groups, but were
significantly higher in the ILP group with 4.8 mg kg-'. The
peak concentration in this 4.8 mg kg-' in ILP group was 3-4
times higher than in the two other groups (ILP 4.8 mg kg-'
group, 2147 ng g-'; ILP and HAI 1.2 mg kg' groups, 668
and 671 ng g'l).
In eight out of nine cases the mean tissue concentrations
were higher in the poorly vascularised tumour (histologically
determined, central necrosis present in tumours growing
above 3-5 mm) than in liver tissue (Figure 5). This was most
pronounced in the ILP with 4.8 mg kg-' group. At t = 5 min
the difference was significant (P <0.05). The peak concentra-
tion in the ILP with 4.8 mg kg-' group was three and five
times higher than in the ILP and HAI with 1.2 mg kg-'
groups respectively (ILP 4.8 mg kg-' group, 3366 ng g-'; ILP
and HAI 1.2mgkg-' groups, 1328 and 724 ng g-').
Discussion
Dose increase of mitomycin C is limited by systemic toxic
side-effects: delayed myelosuppression, pulmonary, cardiac
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Figure 5 Mean liver (U) and tumour (O) tissue concentrations
of mitomycin C in three treatment groups: (1) HAI with
1.2mgkg' (n =5); (2) ILP with 1.2mgkg-' (n =6) and (3)
ILP with 4.8 mg kg-' (n = 6). In each group biopsies of liver
tissue and a whole tumour were taken at 5, 15 and 20min after
bolus administration of the dose and tissue concentrations of
MMC were measured using HPLC.
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and renal toxicity (Crooke & Bradner, 1976; Gunstream et
al., 1983; Chang et al., 1986; Verweij et al., 1987; Cattell,
1985). In the present study we first evaluated whether a
higher dose of mitomycin C could be administered in ILP
setting than via HAI and whether dose increase was limited
by liver or systemic toxicity. Subsequently, rats were treated
with the respective maximally tolerated doses of mitomycin C
in ILP and HAI setting and mitomycin C concentrations
were measured in liver tissue and in plasma to be able to
correlate the differences in toxicity pattern with differences in
tissue and plasma concentrations. Furthermore, tumour tis-
sue concentrations were measured to ascertain that the higher
doses resulted in higher tumour tissue concentrations. We
demonstrated that quite high doses of mitomycin C could be
delivered to the liver. All rats treated with 4.8 mg kg-' by
ILP survived the 'therapy', while bolus infusion of
1.5 mg kg-' by HAI was already 100% lethal.
After ILP treatment with 4.8 mg kg-', SGOT and SGPT
were 3-4 times normal during the first two post-operative
weeks indicating some liver cell damage. Since the serum
potassium levels were within normal range during the blood
sample analysis the increased SGPT levels in this study were
not due to haemolysis but to liver cell damage. Bilirubin was
even more elevated (7-10 times normal) but turned to nor-
mal values within 6 weeks. These results indicate that in ILP
setting 4.8 mg kg-' (four times the maximally tolerated dose
in hepatic artery infusion setting) can still be tolerated. Toxi-
city is transient and confined to the liver. Five times the
maximally tolerated dose in HAI setting (6.0 mg kg-') was
100% lethal within 3 days. Severe liver toxicitity led to
multiple infarction and massive hepatocellular necrosis. In a
clinical study evaluating intensive mitomycin C therapy and
autologous bone marrow transplantation liver toxicity had
been observed too. This therapy resulted in veno-occlusive
disease of the liver in six out of 29 patients (Lazarus et al.,
1982). In our rat study autopsy did not show any of the
characteristic signs of veno-occlusive disease of the liver in
any rat.
Three days after ILP all rats had a significant increase in
the white blood cell count instead of the significant decrease
in white blood cell count that was seen in all rats treated with
HAI. These results clearly demonstrate that in the ILP set-
ting liver toxicity rather than systemic toxicity is dose-
limiting.
When rats were treated with 1.2 mg kg-' via HAI the only
signs of toxicity were weight loss during the first 2 weeks
after bolus administration of mitomycin C and a white blood
cell count dip in the first week. When rats were treated with
doses higher than 1.2 mg kg-' again the myelosuppressive
effect of mitomycin C was seen in the first week after HAI
only. However, 4 weeks after administration of the lethal
dose the urea levels started to increase and the rats died
within 10 days with 3-4 times normal urea levels. The rise in
serum urea levels concurred with the onset of the second fall
in weight (Figure la). Severe weight loss resulting in
increased protein catabolism could be responsible for this
high urea level.
Macroscopic inspection at autopsy revealed no signs of the
toxic side effects of mitomycin C as described by others:
pulmonary toxicity (Gunstream et al., 1983), cardiac toxicity
(Levillain & Cluzan, 1973; Ganz et al., 1983) and renal
toxicity (Cattell, 1985; Verweij, 1986). Although the actual
cause of death is unknown, rats treated with doses of
mitomycin C higher than the maximally tolerated dose most
probably were killed by delayed systemic toxicity.
The difference in toxicity pattern seen in ILP and HAI
treated rats corresponded well with the differences in the
concentrations measured in plasma and in liver tissue.
Apparently there was minimal leakage from the isolated
circuit to the systemic circulation, during and after perfusion,
since the concentration of mitomycin C in plasma was
significantly lower in the two ILP groups than in the HAI
group. The liver tissue concentration in the rats treated with
1.2 mg kg-' was almost identical in the ILP and HAI groups
and in both groups no sign of liver toxicity was observed. In
contrast the much higher liver tissue concentration in the
4.8 mg kg' treated rats obviously was toxic to the liver.
In this study the ILP technique (Brauw et al., 1988) was
extended with a cannula in the gastroduodenal artery as a
second infusion limb in the perfusion circuit. This hepatic
arterial infusion limb is essential since established liver meta-
stases receive most of their blood supply from the hepatic
artery (Ackerman, 1974; Izumi et al., 1986; Sigurdson et al.,
1987). Employing this ILP technique, with two inflow limbs
in the perfusion circuit, the tumour tissue concentrations
were at least as high as the liver tissue concentrations. This is
remarkable since the tumour tissue is poorly vascularised
compared with the liver tissue. In the ILP with 4.8 mg kg-'
group the mean tissue concentrations in tumour were even
much higher than in liver (t = 5 min, P <0.05). A possible
explanation for the relatively high tumour tissue concentra-
tions could be a more rapid metabolism of mitomycin C in
liver than in tumour tissue. The antitumour effect of ILP
with mitomycin C is currently under investigation.
Preliminary results indicate that ILP with the highest dose is
very successful. Complete remissions are observed after ILP,
but not after HAI (manuscript is in preparation).
Schneider et al. (1989) demonstrated that mitomycin C is
still a drug of interest for chemotherapeutic treatment of
colorectal cancer. They conclude that intrahepatic mitomycin
C has a definite salvage benefit in some patients with hepatic
metastases from colorectal carcinoma previously treated with
intrahepatic FUDR. We conclude that if in man, like in the
rats in this study, hepatic metastases can be exposed to much
higher doses of mitomycin C by ILP, this therapeutic option
may be of clinical value.
This study was supported by grant IKW 88-07 from the Dutch
Cancer Foundation.
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